Venrock Healthcare Capital Partners III, L.P.
CIK: 0001738048
Venrock Healthcare Capital Partners III, L.P.'s purchase track record
Venrock Healthcare Capital Partners III, L.P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2025 | ORKA | $1.41M | -10.6% | +19.6% | +5.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ORKA | ▲ Buy | Open Market | 88,794 | $1.0M | 2/14/2025 | View on chart |
| ORKA | ▲ Buy | Open Market | 14,950 | $174K | 2/13/2025 | View on chart |
| ORKA | ▲ Buy | Open Market | 8,971 | $106K | 2/12/2025 | View on chart |
| ORKA | ▲ Buy | Open Market | 9,593 | $105K | 2/11/2025 | View on chart |
| ORKA | ▲ Buy | Open Market | 574 | $6K | 2/10/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.